NCT00379145 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 20
- units
- Participants
- groups
- description
- Trabectedin 1.5 mg/m2 IV over 24 hours every 3 weeks (one cycle) until disease progression or adverse effects prohibit further therapy
- id
- BG000
- title
- Trabectidin
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- title
- <40 years
- measurements
- group Id
- BG000
- value
- 3
- title
- 40-49 years
- measurements
- group Id
- BG000
- value
- 5
- title
- 50-59 years
- measurements
- group Id
- BG000
- value
- 7
- title
- 60-69 years
- measurements
- group Id
- BG000
- value
- 3
- title
- 70-79 years
- measurements
- group Id
- BG000
- value
- 1
- title
- >79 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 20
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 4
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 15
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- Eligible and treated patients
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 20
- units
- Participants
- groups
- description
- Trabectedin 1.5 mg/m2 IV over 24 hours every 3 weeks (one cycle) until disease progression or adverse effects prohibit further therapy
- id
- BG000
- title
- Trabectidin
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- title
- <40 years
- measurements
- group Id
- BG000
- value
- 3
- title
- 40-49 years
- measurements
- group Id
- BG000
- value
- 5
- title
- 50-59 years
- measurements
- group Id
- BG000
- value
- 7
- title
- 60-69 years
- measurements
- group Id
- BG000
- value
- 3
- title
- 70-79 years
- measurements
- group Id
- BG000
- value
- 1
- title
- >79 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 20
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 4
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 15
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- Eligible and treated patients
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle